【摘要】 目的探讨依达拉奉对急性脑梗死(ACI)患者高敏C反应蛋白(hsCRP)含量及预后影响。方法选择ACI患者72例,随机分为治疗组与对照组各36例,在常规治疗的基础上,治疗组予依达拉奉30 mg静脉滴注,每日2次;对照组予奥拉西坦4.0 g静脉滴注,每日1次,疗程7 d。检测血清hsCRP、神经功能缺损和日常生活能力。结果治疗组在治疗后第7、14天hsCRP水平明显低于对照组(P<0.05);第7、14天欧洲脑卒中评分量表评分高于对照组,第7、14、30、90天日常生活活动量表评分均高于对照组(P<0.05)。结论依达拉奉可明显减轻ACI患者炎性反应,改善缺损神经功能和日常生活能力。更多还原

【Abstract】 Objective To observe the clinical effects of edaravone on high sensitivity C-reactive protein(hsCRP)and prognosis in patients with acute cerebral infarction(ACI).Methods 72 patients with ACI were randomly divided into study group and control group(n=36),on the basis of conventional treatment,study group were treated with edaravone of 30 mg intravenously(twice a day),control group were treated with oxiracetam of 4.0 g intravenously(once a day)respectively.All treated for 7 days.The level of serum hsCRP was measured by immunomephelometry pretreatment and on the 7th day and the 14th day post-treatment;the European stroke scale(ESS)and activity of daily living(ADL)were scored.Results The level of serum hsCRP on the 7th day and the 14th day post-treatment in the study group was significantly decreased than that in the control group(P<0.05),the score of ESS on the 7th,14th,the score of ADL on the 7th,14th,30th and 90th day in the study group was significantly increased than that in the control group(P<0.05).Conclusion Edaravone can decrease the level of inflammatory reaction,improve impaired neurologic function and daily living activity.更多还原